Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension

Name: Verified Rigor Record — Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension
Item: Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension
Rating: 96
Author: Αlpha¹

Flack JM, Azizi M, Brown JM, Dwyer JP, Fronczek J, Jones ESW, Olsson DS, Perl S, Shibata H, Wang JG, Wilderäng U, Wittes J, Williams B, BaxHTN Investigators.

Paper source

Open DOI

Αlpha¹ Rigor Review

Rigor Review Verified

Critical

High-priority

Action items to resolve · Critical / High

Confidence: highEngine: 7.5.0Source: full text

This Alpha1 Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This phase 3 RCT is methodologically robust: it uses a randomized, double-blind, placebo-controlled design with adequate power, proper ethics approvals, and transparent reporting. The main weakness is the lack of a concrete data availability statement for individual patient data, and several minor reporting omissions (e.g., no CONSORT checklist citation, no software version, power analysis without effect-size justification).

Three independent reviewers evaluated all eight dimensions using a standard checklist; they converged strongly on most dimensions (disagreements were minor and resolved by weighting evidence). The statistics verification recomputed 14 of 15 reported tests consistently; no errors were found. The citation check found no retracted or missing references. The copyedit pass identified nine minor issues (typos, consistency).

12 major claims checked against the paper's own evidence: all adequately supported.

partialDiscussion, paragraph 4
The slow offset of baxdrostat's effect on BP is consistent with its mechanism of action on sodium homeostasis.
The claim is speculative and supported by indirect evidence (slow BP offset, aldosterone/PRA not returning to baseline), but no direct mechanistic data are presented.
Evidence: Discussion paragraph 4: 'We speculate that the slow offset of baxdrostat's effect on BP is consistent with its mechanism of action on sodium homeostasis.'
“We speculate that the slow offset of baxdrostat's effect on BP is consistent with its mechanism of action on sodium homeostasis.”
partialResults, Safety section
Baxdrostat is safe and generally well-tolerated.
The safety data are presented and show low rates of serious AEs across groups, but hyperkalemia and hyponatremia occur more with baxdrostat than placebo, and the claim of 'well-tolerated' is subjective. The data presented supports a favorable risk-benefit but does not prove safety.
Evidence: Table 3 and safety results text.
“Serious AEs occurred in 5 (1.9%), 9 (3.4%) and 7 (2.7%) participants receiving baxdrostat 1 mg, baxdrostat 2 mg and placebo, respectively. ... Hyperkalemia and hyponatremia occurred more frequently in the baxdrostat groups versus placebo.”
partialDiscussion and Conclusion
Baxdrostat represents a new therapeutic option for hard-to-control hypertension.
The efficacy and safety data are positive, but the claim of being a 'new therapeutic option' is implied, not explicitly stated as a conclusion. The paper shows efficacy but does not compare head-to-head with other therapies like MRAs, which are the current standard for resistant hypertension.
Evidence: Discussion and conclusion.
“In conclusion, baxdrostat when added to background antihypertensive therapy resulted in a reduction in seated-SBP at 12 weeks compared with placebo in a broad population of patients with uncontrolled and resistant hypertension.”
partialResults, Secondary End Points
The BP-lowering effect is consistent across pre-specified subgroups.
A forest plot (Figure 2) is shown, but the widths of CIs are unadjusted for multiplicity and the paper notes this. The subgroup effects appear consistent, but the analysis is descriptive and not hypothesis-driven.
Evidence: Figure 2 and text: 'Treatment effects by pre-specified subgroups ... are presented in [Figure and Supplementary Appendix]'.
“BP changes were similar in pre-specified subgroups”
supportedAbstract, Conclusions
Baxdrostat added to background therapy resulted in a reduction in seated-SBP at 12 weeks compared with placebo in patients with uncontrolled or resistant hypertension.
The primary endpoint results (LS mean differences of -8.7 and -9.8 mmHg, both P<0.0001) directly support this claim.
Evidence: Table 2 and Results section: LS mean placebo-corrected differences with 95% CIs and p-values.
“Baxdrostat added to background therapy resulted in a reduction in seated-SBP at 12 weeks compared with placebo in patients with uncontrolled or resistant hypertension.”
supportedDiscussion, paragraph 3
The BP lowering effects of baxdrostat were consistent with those reported for the aldosterone synthase inhibitor lorundrostat.
The paper cites a phase 3 trial of lorundrostat with a similar placebo-adjusted reduction (-9.1 mmHg) and notes consistency.
Evidence: Discussion paragraph 3: 'The BP lowering effects of baxdrostat in our study were consistent with those reported for the aldosterone synthase inhibitor lorundrostat.'
“The BP lowering effects of baxdrostat in our study were consistent with those reported for the aldosterone synthase inhibitor lorundrostat.”
supportedDiscussion, paragraph 5
The safety data with baxdrostat were generally consistent with lorundrostat clinical trials.
The paper compares safety findings (hyperkalemia, hyponatremia, eGFR changes) with those reported for lorundrostat, noting consistency.
Evidence: Discussion paragraph 5: 'In our study, the 12-week safety data with baxdrostat were generally consistent with lorundrostat clinical trials.'
“In our study, the 12-week safety data with baxdrostat were generally consistent with lorundrostat clinical trials.”
supportedAbstract and Results
Baxdrostat reduces seated SBP compared with placebo in uncontrolled and resistant hypertension.
The primary endpoint results (LS mean differences of -8.7 and -9.8 mmHg, both P<0.0001) directly support this claim.
Evidence: Table 2 and Figure 1: primary endpoint change from baseline to week 12.
“At week 12, change from baseline in least-squares mean seated-SBP for baxdrostat 1mg was –14.5 mmHg (95% CI, –16.5 to –12.5); baxdrostat 2mg, –15.7 mmHg (–17.6 to –13.7); versus placebo, –5.8 mmHg (–7.9 to –3.8). Estimated treatment differences ... –8.7 mmHg (95% CI, –11.5 to –5.8; P<0.0001) and – 9.8 mmHg (–12.6 to –7.0; P<0.0001), respectively.”
supportedResults, Secondary End Points
Baxdrostat is effective in the resistant hypertension subpopulation.
The pre-specified secondary analysis in resistant hypertension shows significant reductions of -9.1 and -9.8 mmHg, both P<0.0001.
Evidence: Table 2 and Figure 1: secondary endpoint in resistant hypertension.
“In the resistant hypertension subpopulation, LS mean estimated placebo-corrected treatment differences in seated-SBP change at week 12 were –9.1 mmHg (95% CI, –12.6 to –5.7; P<0.0001) with baxdrostat 1 mg and –9.8 mmHg (95% CI, –13.1 to –6.4; P<0.0001) with baxdrostat 2 mg.”
supportedResults, Secondary End Points and Discussion
The BP lowering effect of baxdrostat is sustained after withdrawal, suggesting a slow offset of action.
The randomized withdrawal period (part 3) shows a significant difference of -5.1 mmHg (P=0.0016) between baxdrostat 2mg and placebo, supporting a sustained effect.
Evidence: Table 2 and Figure 1: secondary endpoint for randomized withdrawal.
“The change in LS mean seated-SBP during the randomized withdrawal period was –3.7 mmHg (95% CI, –5.5 to –1.9) with baxdrostat 2 mg and +1.4 mmHg (95% CI, –1.2 to 4.0) with placebo (estimated difference of –5.1 mmHg [95% CI, –8.3 to –1.9; P=0.0016]).”
supportedResults and Discussion
Baxdrostat's mechanism involves aldosterone synthase inhibition leading to reduced aldosterone and increased PRA.
Exploratory endpoint data on aldosterone and PRA, mentioned in the results and discussion, support the mechanism. The paper states these are not hypothesis-tested but observations are consistent.
Evidence: Exploratory endpoints and Discussion.
“Though not subject to hypothesis testing, we noted reduced aldosterone and increased PRA levels that might suggest that baxdrostat may induce further urine sodium excretion...”
supportedAbstract, Results, Primary End Point
Baxdrostat reduced seated-SBP compared with placebo at week 12 in patients with uncontrolled or resistant hypertension.
The primary endpoint data directly support this: LS mean differences of -8.7 and -9.8 mmHg, both with p<0.0001 and 95% CIs excluding zero.
Evidence: Primary endpoint results: Table 2 and Figure 1.
“Baxdrostat added to background therapy resulted in a reduction in seated-SBP at 12 weeks compared with placebo in patients with uncontrolled or resistant hypertension.”

Recomputed 14 tests: 14 consistent, 0 inconsistent, 14 via agent-written checks.

2 integrity concerns flagged (0 high).

Rigor

Eight Dimensions7 pass · 1 warn

12 major claims4 partial8 supported

9 copyedit issues flagged: mostly consistency, typo, grammar.

Checked 25 references: 25 verified.

Reproducibility

3 data/code links checked; 2 live.

datahttps://nejm.org/UNVERIFIEDHTTP 403
Liveness indeterminate — content not checked.
datahttps://clinicaltrials.gov/study/NCT06034743LIVEHTTP 200
Resolves, but the content could not be matched to the paper.
datahttps://clinicaltrials.gov/study/NCT06168409LIVEHTTP 200
Resolves, but the content could not be matched to the paper.

Registered (2 IDs: ClinicalTrials.gov). No reporting guideline cited.

Alpha¹ Rigor Action ItemsFinal pass before journal submission

The paper is robust overall; its primary conclusions (baxdrostat reduces seated SBP vs placebo) are supported by the reported data and analyses. An informed reader should note the lack of a concrete data sharing statement (IPD access not described) and the minor reporting gaps (missing CONSORT, software version, effect-size justification for power analysis). None of these undermine the validity of the findings, but they would warrant an erratum or correction to improve transparency.

1.
HIGHdata code
Add a data availability statement specifying a managed-access platform (e.g., Vivli, YODA, or sponsor data request process) or a clear contact for requesting individual participant data.
The paper currently lacks an explicit statement about where IPD can be accessed, which is an integrity gap for a published clinical trial.
2.
HIGHreporting
Add a statement confirming the trial was reported in accordance with the CONSORT 2010 checklist, and include the checklist as supplemental material.
Clinical trial reporting standards expect reference to a reporting guideline; its absence is a minor but noticeable gap.
3.
HIGHrigor
In the power analysis description, provide the clinical justification or prior evidence for assuming a 6 mmHg (SD 15) treatment effect.
The effect size assumption is critical to the power calculation; its justification is missing, which reduces transparency about trial planning.
4.
HIGHstatistics
Specify the SAS version used for all analyses (e.g., SAS 9.4) in the Statistical Analyses section.
Software version is a basic reproducibility detail; its omission is a minor but pervasive reporting gap across clinical trials.
5.
MEDIUMcopyedit
Correct the typo 'Hyperkaemia' to 'Hyperkalemia' and add the missing closing parenthesis in the Results, Safety paragraph.
Typographical errors in medical terminology may confuse readers and should be corrected via erratum.
6.
MEDIUMcopyedit
Rephrase the eGFR sentence in Results, Safety paragraph to eliminate the suspicious duplication of >30% and ≥30% values and clarify the structure.
The identical reported percentages for >30% and ≥30% eGFR decline are confusing and likely a typo; correction is needed for data clarity.
7.
MEDIUMcopyedit
Add a footnote to Table 3 explaining why denominators vary across potassium threshold rows (e.g., 'Denominators represent subjects not meeting the criterion at baseline').
The varying denominators (248, 260, 262, 263 for placebo) are confusing without a clear explanation; the current footnote is insufficient.
8.
MEDIUMreporting
Include the key exclusion criteria in the main Methods section rather than deferring entirely to the Supplementary Appendix.
Key exclusion criteria are important for understanding the study population; deferring them fully may reduce accessibility for readers without supplement access.
9.
MEDIUMcopyedit
In the Abstract Results, provide the denominator for the percentage reporting potassium >6.0 mmol/l (e.g., '1/264 [0.4%]') for consistency with the main Results.
The abstract omits the denominator, which is inconsistent with the detailed reporting elsewhere and could mislead readers about the sample size.
10.
LOWrigor
In the Statistical Analysis section, mention that the assumptions of ANCOVA (normality of residuals, homogeneity of variance) were assessed, or note that the large sample size makes the test robust.
Explicit statement about assumption verification adds confidence to the analysis; currently it is implied but not stated.
11.
LOWreporting
Include a code availability statement noting whether the sponsor's analysis code is available upon request.
Even if code is not shared, stating that it is available upon request would improve transparency for potential re-analyses.

Full text (41,281 chars)Analyzed: Jul 5, 2026

Αlpha¹ assesses methodological rigor, not the importance of the findings. See how we calibrate →